PDCD1 and neoplasm: Considering both the therapeutic benefit and the risk of side effects, in cases with positive tumor cell PD-L1 staining (>5%), anti-PD-1 monotherapy is advantageous, while, in negative cases, combination with anti-CTLA-4 could be more advantageous [52].